This Keystone Symposia Myeloid Cells meeting will bring together leaders from academia and industry to discuss the latest insights into myeloid cell heterogeneity and how these cells can be harnessed for therapeutic benefit. Although myeloid cells hold tremendous therapeutic promise, this potential has yet to be fully realized. Unlike previous meetings that focused primarily on academic advances, this program will also highlight cutting-edge industry approaches and translational applications, fostering collaboration across sectors to accelerate therapeutic innovation. 

A key theme will be translating recent discoveries into actionable therapies, including how single-cell RNA-seq studies have revealed both unique and conserved myeloid populations across tissues and diseases. Discussions will address pivotal questions for the field: How can these insights be leveraged therapeutically? What emerging technologies will drive future breakthroughs? 

The meeting will also provide trainees with valuable perspectives on how science is conducted in both academic and industrial settings, offering insight into the process of therapy discovery and development. 

Joint Meeting with “Hematopoiesis: From Stem Cells to Function and Disease” 
Held in conjunction with the Hematopoiesis meeting, this joint event will provide an integrated view of how hematopoietic stem cells and myeloid lineages intersect in health and disease. Shared sessions and networking opportunities will enrich discussions and catalyze new collaborations across both fields. 

In the video below, Dr. Charlotte Scott from the University of Ghent & VIB, talks about what to expect from this meeting and why you should attend:

Additionally, check out some of the speaker highlights: